| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P2093 | author name string | D. D. Mitsikostas | |
| S. Konitsiotis | |||
| P. Stathis | |||
| M. Smpiliris | |||
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| When words are painful: unraveling the mechanisms of the nocebo effect | Q31106595 | ||
| Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches | Q34158126 | ||
| Nonspecific medication side effects and the nocebo phenomenon | Q34519096 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| Scales to assess the quality of randomized controlled trials: a systematic review | Q34724144 | ||
| Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses | Q34746177 | ||
| The nocebo effect and its relevance for clinical practice | Q35196454 | ||
| Lessons from placebo effects in migraine treatment | Q36332377 | ||
| New insights into the placebo and nocebo responses | Q37230629 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| A systematic review of adverse events in placebo groups of anti-migraine clinical trials | Q37603565 | ||
| Milestones in movement disorders clinical trials: Advances and landmark studies | Q37882584 | ||
| Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice | Q37942656 | ||
| Nocebo in Headaches: Implications for Clinical Practice and Trial Design | Q37970944 | ||
| Placebo influences on dyskinesia in Parkinson's disease | Q40136999 | ||
| Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism. | Q42499144 | ||
| A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. | Q43662938 | ||
| Nocebo effects in multiple sclerosis trials: a meta-analysis | Q46822234 | ||
| Conducting Meta-Analyses in R with the metafor Package | Q58423162 | ||
| The nocebo reaction | Q79032458 | ||
| The Combination of Estimates from Different Experiments | Q100745541 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nocebo | Q1332954 |
| Parkinson's disease | Q11085 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 527-533 | |
| P577 | publication date | 2012-11-12 | |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis | |
| Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta‐analysis | |||
| P478 | volume | 20 |
| Q38219326 | Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. |
| Q38711711 | Analysis of nocebo effects of antiepileptic drugs across different conditions |
| Q38259757 | Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies. |
| Q35061374 | Expectation modulates the effect of deep brain stimulation on motor and cognitive function in tremor-dominant Parkinson's disease |
| Q90472102 | How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions |
| Q44863430 | Minimizing nocebo effect: Pragmatic approach |
| Q50616272 | Nocebo effects and psychotropic drug action |
| Q92510498 | Nocebo in Biosimilars and Generics in Neurology: A Systematic Review |
| Q38736906 | Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials |
| Q35387933 | Nonspecific adverse events in knee osteoarthritis clinical trials: a systematic review |
| Q90472115 | Placebo analgesia effects across central nervous system diseases: what do we know and where do we need to go? |
| Q85366029 | Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation |
| Q59789438 | Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials |
| Q38972857 | Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. |
Search more.